CervoMed Shares Neflamapimod Development Update
BOSTON, August 5, 2026 CervoMed announced that its management team will participate in a fireside chat and investor meetings...
ALS
Advertisement
Ractigen Therapeutics Closes $31M Financing to Advance saRNA Pipeline
NANTONG, China, July 29, 2026 Ractigen Therapeutics has successfully closed a financing round exceeding $31 million (over RMB 200...
AB Science Prioritizes AML and ALS Programs
PARIS, July 10, 2026 AB Science announced a major strategic update to its clinical development pipeline, confirming that it...
NKGen Biotech to Highlight Troculeucel Alzheimer’s Program at BIOCHINA Forum
SANTA ANA, Calif., July 2, 2026 NKGen Biotech announced that Chairman and Chief Executive Officer Paul Y. Song, M.D.,...
Chiesi, Arbor Secure EU Orphan Status for ABO-101
PARMA, Italy & CAMBRIDGE, Mass., June 25, 2026 Chiesi Group and Arbor Biotechnologies have achieved a significant regulatory milestone...
Advertisements
Ionis Partners with Recordati to Expand Zilganersen Globally
CARLSBAD, Calif., June 25, 2026 Ionis Pharmaceuticals has entered into a landmark global licensing agreement with Recordati to accelerate...
Anivive Wins FDA Approval for First Oral Canine Lymphoma Drug
LONG BEACH, Calif., June 26, 2026 Anivive Lifesciences has achieved a landmark milestone after the U.S. Food and Drug...
NeuroSense PrimeC Shows Positive Phase 2 Alzheimer’s Biomarker Data
CAMBRIDGE, Mass., June 25, 2026 NeuroSense Therapeutics Ltd. announced positive biomarker findings from its Phase 2 randomized, double-blind, placebo-controlled...
Lilly Completes Centessa Deal to Accelerate Treatments for Narcolepsy and Sleep-Wake Disorders
INDIANAPOLIS, June 24, 2026 Eli Lilly and Company announced the successful completion of its acquisition of Centessa Pharmaceuticals plc,...
AL-S Pharma Reports Positive Phase 2 AP-101 Data at ENCALS 2026
ZURICH, Switzerland, June 24, 2026 AL-S Pharma AG announced positive Phase 2 clinical results for its lead investigational antibody...
Advertisement
